An open-label extension trial assessing the safety and tolerability of [S,S]-reboxetine in patients with postherpetic neuralgia (PHN)
Phase of Trial: Phase II
Latest Information Update: 21 Apr 2011
At a glance
- Drugs Esreboxetine (Primary)
- Indications Postherpetic neuralgia
- Focus Adverse reactions
- Sponsors Pfizer
- 06 Apr 2011 Actual patient number and end date added, as reported by ClinicalTrials.gov.
- 17 Jul 2008 Status changed from in progress to discontinued, from clincialtrials.gov record.
- 09 Aug 2007 Status changed from recruiting to in progress.